Cablivi (caplicizumab-yhdp)
Effective 01/01/2022

<table>
<thead>
<tr>
<th>Plan</th>
<th>MassHealth</th>
<th>Commercial/Exchange</th>
<th>Program Type</th>
<th>Prior Authorization</th>
<th>Quantity Limit</th>
<th>Step Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefit</td>
<td>Pharmacy Benefit</td>
<td>Medical Benefit (NLX)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialty Limitations</td>
<td>This medication has been designated specialty and must be filled at a contracted specialty pharmacy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Specialty Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Plans</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Specialty Medications</td>
</tr>
<tr>
<td>MassHealth</td>
</tr>
<tr>
<td>Commercial</td>
</tr>
<tr>
<td>Exchange</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medical Specialty Medications (NLX)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Plans</td>
</tr>
</tbody>
</table>

Exceptions
N/A

Overview
Cablivi is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Coverage Guidelines
Authorization may be granted for a total of 30 days for members who are currently receiving treatment with Cablivi excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR
Authorization may be granted for members when all the following criteria are met, and documentation is provided:
1. The member has a diagnosis is acquired thrombotic thrombocytopenic purpura (aTTP) after receiving plasma exchange in the inpatient setting
2. The requested medication will be given in combination with immunosuppressive therapy.
3. Member is ≥ 18 years of age
4. Therapy is prescribed by or in consultation with a hematologist

Continuation of Therapy
Reauthorizations are limited to 28 days of therapy for continuation when all the following criteria is met:

a. The member has either of the following documented signs of persistent underlying aTTP:
   i. ADAMTS13 activity level less than 10% or
   ii. All of the following:
      1. Microangiopathic hemolytic anemia (MAHA) documented by the presence of schistocytes on peripheral smear
2. Thrombocytopenia (platelet count below normal per laboratory reference range), and
   b. Elevated lactate dehydrogenase (LDH) level (LDH level above normal per laboratory reference range)
   c. The requested medication will be given in combination with immunosuppressive therapy.
   d. The member has not received a prior 28 day extension of therapy after the initial course of the requested medication for this course of treatment.
   e. The member has not experienced more than 2 recurrences of aTTP while on the requested medication. (A recurrence is when the patient needs to reinitiate plasma exchange. A 28-day extension of therapy does not count as a recurrence.)

Limitations
1. Initial approvals are limited to 30 days of therapy
2. Reauthorizations are limited to 28 days of therapy

References

Review History
09/22/2021 – Reviewed at Sept P&T; no clinical changes; separated out MH vs. Comm/Exch. Effective 01/01/2022

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.